Entering text into the input field will update the search result below

Acceleron Pharma up 7% on FDA nod for luspatercept

Nov. 08, 2019 1:25 PM ETMerck & Co., Inc. (MRK) Stock, CELG StockBy: Douglas W. House, SA News Editor3 Comments
  • Acceleron Pharma (XLRN +7%) and collaboration partner Celgene (NASDAQ:CELG +0.4%) announce FDA approval of Reblozyl (luspatercept-aamt) for the treatment of anemia in adult beta thalassemia patients who require regular red blood cell transfusions.
  • The companies will co-promote the product in the U.S.

Recommended For You

Related Stocks

SymbolLast Price% Chg
CELG
--
MRK
--